Senti Biosciences Holdings (SNTI) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History and Financial Condition

1. 01We are an early stage clinical biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability
2. 02incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company
3. 03We will need substantial additional funds to advance development of product candidates and our gene circuit platform, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future product candidates and technologies
4. 04our efforts to enhance operational systems and to hire and retain personnel, including personnel to support development of our product candidates and to satisfy our obligations as a public company
5. 05arrangements, grants and other marketing and distribution arrangements. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved
6. 06Our streamlining of business operations, including workforce reduction and re-prioritization plan announced in January 2024, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business
7. 07A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis
8. 08Members of our management team have limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company
9. 09Our ability to use net operating loss carryforwards (“NOLs”) and credits to offset future taxable income may be subject to certain limitations
10. 10The sale or issuance of our common stock to Celadon Partners may cause significant dilution and the sale of the shares of common stock acquired by Celadon Partners, or the perception that such sales may occur, could cause the price of our common stock to fall
11. 11closure of or reorganization of such financial institution and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis

Risks Related to the Development and Clinical Testing of Our Product Candidates

1. 12Our current product candidates are in early clinical or preclinical development. One or all of our current product candidates may fail in clinical development or suffer delays that materially and adversely affect their commercial viability
2. 13the FDA or other regulatory authorities interpreting our data differently than we do
3. 14Clinical trials of our current or potential future product candidates may not demonstrate the safety, purity and potency, or efficacy, necessary for such product candidates to become approvable or commercially viable
4. 15Our gene circuit platform technologies are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval
5. 16We may not be successful in our efforts to use and expand our gene circuit platform to grow our pipeline of product candidates
6. 17an approved product may not be accepted as safe and effective by patients, the medical community or third-party payors
7. 18The market, physicians, patients, regulators and potential investors may not be receptive to our current or potential future product candidates and may be skeptical of the viability and benefits of our gene circuit pipeline technology because it is based on a relatively novel and complex technology
8. 19We may not be able to file additional INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
9. 20We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline
10. 21Clinical trials are expensive, time-consuming and difficult to design and implement
11. 22If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
12. 23factors we may not be able to control, such as potential pandemics that may limit the availability of patients, principal investigators or staff or clinical sites to participate in our clinical trials
13. 24If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to seek or obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue
14. 25the suspension or termination of our clinical trials upon a breach or pursuant to the terms of any agreement with, or for any other reason by, any future strategic collaborator that has responsibility for the clinical development of any of our product candidates
15. 26If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop
16. 27We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities

Risks Related to Our Reliance on Third Parties

1. 28There can be no assurance that we will achieve all of the anticipated benefits of the transaction with GeneFab and we could face unanticipated challenges
2. 29We currently rely and intend to continue to rely on third parties to conduct our clinical trials and preclinical studies, and those third parties may not perform satisfactorily
3. 30As a result, we may not be able to conduct these collaborations in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations
4. 31uses our proprietary information or intellectual property in such a way as to jeopardize our rights in such property
5. 32the inability to retain key employees of any acquired business
6. 33any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and technologies and have a negative impact on the competitiveness of any product candidate or technology that reaches market

Risks Related to Manufacturing

1. 34consistently and reliably manufacture any current and future products and we are required to rely on third-party back-up manufacturers
2. 35Each of these risks could delay or have other adverse impacts on our clinical trials and the approval and commercialization of our product candidates, potentially resulting in higher costs, reduced revenues or both
3. 36in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products
4. 37We are exposed to a number of risks related to our supply chain for the materials required to manufacture our product candidates
5. 38Changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay

Risks Related to Our Business and Operations

1. 39If the market opportunities for our current and potential future product candidates, including SENTI-202 and SENTI-301A, are smaller than we believe they are, our future product revenues may be adversely affected, and our business may suffer
2. 40Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan
3. 41On February 25, 2025, we announced the appointment of Jay Cross as our Chief Financial Officer effective March 3 2025, and principal financial officer and principal accounting officer, effective following our filing the Company’s Annual Report on Form 10-K for the year ended December 31, 2024
4. 42We may experience difficulties in managing our growth and expanding our operations
5. 43Our commercial relationships with entities outside of the United States and our potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States
6. 44certain expenses including, among others, expenses for travel, translation and insurance; and
7. 45Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations and prospects
8. 46Our employees, principal investigators, consultants and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
9. 47If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
10. 48may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations
11. 49Market volatility and economic downturns may harm our business and results of operations and negatively affect our stock price
12. 50These developments could lead to supply chain disruption, inflation, higher interest rates, and uncertainty about business continuity, which may adversely affect our business and our results of operations and negatively affect our stock price
13. 51Rising inflation rates could negatively impact our business. If our costs increase, our net losses would increase, which may have a material adverse effect on our business

Risks Related to Our Intellectual Property

1. 52The patent protection and patent prosecution for some of our product candidates and technologies may be dependent on third parties
2. 53We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations
3. 54the priority of invention of patented technology
4. 55Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates
5. 56Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates
6. 57We may be subject to lawsuits or litigation to protect or enforce our patents or other intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products
7. 58our intellectual property rights could be costly to us, could require significant time and attention of our management, and could have a material and adverse impact on our profitability, financial condition and prospects or ability to successfully compete
8. 59We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business
9. 60Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business
10. 61require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology
11. 62Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our shares of our common stock to decline
12. 63product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all, or it may be non-exclusive, which could result in our competitors gaining access to the same intellectual property
13. 64If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 65we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties
15. 66We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of third parties, including our employees’ or consultants’ former employers or their clients
16. 67We may be subject to claims challenging the inventorship of our patents and other intellectual property
17. 68Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
18. 69If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
19. 70Intellectual property rights do not necessarily address all potential threats to our business

Risks Related to Government Regulation

1. 71Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
2. 72Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance
3. 73We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our current or potential future product candidates
4. 74Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
5. 75We may conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business
6. 76diminished protection of intellectual property in some countries
7. 77The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
8. 78The FDA and other regulatory authorities have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed
9. 79Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
10. 80Healthcare legislative or regulatory reform measures may have a material adverse effect on our business and results of operations
11. 81Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business
12. 82If we or our existing or potential future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our product candidates and may harm our reputation
13. 83If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business
14. 84Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
15. 85We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business

Risks Related to Senti and the shares of our common stock

1. 86Our stock price is volatile, and you could lose part of all of your investment
2. 87general economic, industry and market conditions
3. 88We may incur significant costs from class action litigation due to the expected stock volatility
4. 89We are an “emerging growth company” and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the shares of our common stock less attractive to investors and may make it more difficult to compare performance with other public companies
5. 90If certain holders of our common stock sell a significant portion of their securities, it may negatively impact the market price of the shares of our common stock and such holders still may receive significant proceeds
6. 91Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock
7. 92Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
8. 93Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
9. 94Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of shares of our common stock
10. 95The obligations associated with being a public company involve significant expenses and require significant resources and management attention, which may divert from our business operations
11. 96require super majority votes of the holders of our common stock to amend specified provisions of our Charter and Bylaws
12. 97for certain securities law actions, which could limit our stockholders’ ability to litigate disputes with us in a different judicial forum and increase the costs for our stockholders to pursue certain claims against us
13. 98Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be investors’ sole source of gain
14. 99We may be at an increased risk of securities class action litigation
15. 100We have issued a substantial number of warrants which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders
16. 101Future sales, or the perception of future sales, of our securities by existing shareholders or by us could cause the market price for our common stock to decline
17. 102We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
18. 103Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
19. 104changes in general market and economic conditions
20. 105We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
21. 106Our executive officers, directors, principal stockholders and their affiliates exercise significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control